BioPharm America™ 2016: Denmark-based biotech Curasight making strides in cancer therapies

October 10, 2016
CSO and Co-Founder of Curasight Andreas Kjaer spoke with Informa Pharma Intelligence at BioPharm America about his company's efforts to develop novel, innovative radionuclide therapies for cancer. With two completed Phase I trials and an ongoing Phase II study with its lead candidate in breast cancer, this Denmark-headquartered biotech also is developing companion diagnostic PET imaging ligands to improve diagnosis, treatment and outcomes in cancer. Krasilnikoff also talked about Curasight's efforts to raise its profile in North America, including potential partnering talks at BioPharm America in Boston.
Previous Video
Digital Health Showcase 2016: At the intersection of technology and medicine
Digital Health Showcase 2016: At the intersection of technology and medicine

The convergence between technology and medicine is poised to have a profound effect on healthcare, impactin...

Next Video
BPA16 Interview Troy Wilson, Kura Oncology 1
BPA16 Interview Troy Wilson, Kura Oncology 1